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Abstract
Background: Although pharmacotherapy is one of the most important treatments for schizophrenia, the
prominent levels of antipsychotic polypharmacy and high-dose regimens used in Japan are thought to be
inconsistent with treatment regimens used in other countries. In this study, we evaluated the effect of pharmacist
intervention on physician prescribing in patients with chronic schizophrenia.
Methods: Participants comprised 52 inpatients at Sawa Hospital (Osaka, Japan), treated with at least one antipsychotic
agent, who received pharmacist intervention for 1 year (2012). We compared the dose and the number of
antipsychotics prescribed, and the rate of concurrent prescribing of anti-Parkinson, benzodiazepine and mood-stabilizer
medication, pre- and post-pharmacist intervention. As an indicator of psychosis symptoms, the rate of seclusion
room use was recorded. Additionally, we evaluated the impact of pharmacist intervention on medicine costs.
Continuous variables were analyzed by Wilcoxon signed-rank sum tests, and categorical data were analyzed using
Fisher’s exact tests.
Results: Compared with pre-intervention, the dose (982.6 mg pre vs. 857.6 mg post; p < 0.01) and the number of
antipsychotics (2.0 pre vs. 2.0 post; p < 0.05) at 1 year were significantly lower post-intervention. The seclusion
room use rate was not significantly different but tended to be lower post-intervention than pre-intervention
(p < 0.1). The cost (in USD) for all medicines (10.33 pre vs. 8.76 post; p < 0.05), antipsychotics (8.04 pre vs. 6.48
post; p < 0.05), and psychotropics (9.24 pre vs. 7.68 post; p < 0.01) were significantly lower post-intervention
than pre-intervention.
Conclusion: Pharmacist intervention has the potential to optimize medication prescribing and reduce medication
costs in patients with chronic schizophrenia. It might be suggested that clinical practitioners as well as medical hospital
administrators consider the pharmacists’ ability to rationalize medication therapy in schizophrenia.
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Background
Despite the poor and contradictory evidence for the ef-
fectiveness of two or more antipsychotics (anti-
psychotic polypharmacy), it continues to be used in
about one third of patients with chronic schizophrenia
[1]. Disadvantages of polypharmacy include the poten-
tial for increased adverse effects [2, 3] and increased
healthcare costs [4]. Often when managing these ad-
verse effects, rather than stopping the offending medi-
cation, physicians tend to add a new medication to
counteract the adverse effect [5–7]. For example, to
manage the adverse effect of extrapyramidal symptoms,
an anti-Parkinson medication is added, which causes
constipation and a decline in cognitive function. Con-
sequently, patients are prescribed laxatives, and cogni-
tive impairment, an important negative symptom of
schizophrenia, is exacerbated [8, 9]. This continued
cycle warrants improved physician understanding of
the use and effectiveness of medication, and how to
better manage adverse effects.
Traditionally the role of the pharmacist predominantly
involved the dispensing of medications in hospital phar-
macies, and the pharmacist was quite detached from
other healthcare professionals [10]. In Japan, although
pharmaceutical care by clinical pharmacists was initiated
in 1989, this care only guided the use of prescribed med-
icines. In 2010, the Japanese Ministry of Health, Labour,
and Welfare recommended including pharmacists as
part of a multidisciplinary team because pharmacists are
experts on medicines and are responsible for pharmaco-
therapy. In these recommendations, clinical pharmacists
are asked to optimize prescriptions for patients, taking
into account the safety of the pharmacotherapy, espe-
cially for drugs treating psychosis. In countries outside
Japan, the role of the clinical pharmacist had already
evolved and had been recognized as an essential compo-
nent of the multidisciplinary team [11]. These clinical
pharmacists have diversified into expanded areas of care
in hospital practice [12], not only checking prescriptions
but also discussing cases with physicians, nurses, and
other healthcare professionals involved in the care of the
patient as well as proposing optimal therapy. These in-
terventions are integral components of the new, en-
hanced role of the pharmacist in the clinical setting, and
if undertaken judiciously, may prevent errors in pre-
scribing [13, 14].
In this study, we evaluated the usefulness of pharma-




Fifty-two inpatients at Sawa Hospital (Osaka, Japan)
were recruited between October 2010 and October
2012. Patients had a diagnosis of schizophrenia accord-
ing to the Diagnostic and Statistical Manual of Mental
Disorder IV classification and were receiving at least one
antipsychotic agent. Their symptoms and medication
were stable for at least 3 months as determined by their
physicians and by pharmacists examining the patients’
medical histories before inclusion in this study. Exclu-
sion criteria included the presence of symptoms or
severe adverse effects that warranted an immediate
medication change.
This was a two-stage (pre-/post-intervention) study. In
the pre-intervention stage (from 1/11/2010 to 31/10/
2011), patients received usual care (no pharmacist inter-
vention). In the post-intervention stage (from 1/11/2011
to 31/10/2012), patients received pharmacist interven-
tion in addition to usual care.
Pharmacist intervention
For the purposes of the study, the components of
pharmacist intervention to optimize and simplify a
prescription were outlined as follows. 1) Discuss the
decision of polypharmacy and/or excessive anti-
psychotic doses (defined as more than 1000 mg/day
chlorpromazine equivalents). 2) In the discontinuation
of antipsychotic medication, propose gradual tapering.
3) Suggest the addition or discontinuation of concur-
rent medications. 4) Where applicable, recommend
therapeutic monitoring to monitor adverse effects.
There was no limit to the frequency of intervention
provision, to reflect the real clinical setting where in-
terventions are undertaken when deemed appropriate
and not at specified intervals.
Data collection
We recorded the dose and the number of antipsychotics,
the rate of concurrent anti-Parkinson, benzodiazepine,
and mood-stabilizer use and medicine costs. Doses of
antipsychotics were expressed as chlorpromazine equiva-
lents [15]. For patients receiving two or more antipsy-
chotics, the total combined dose was calculated. Data
recorded for the pre-stage (at 31/10/2011) was com-
pared with the post-stage (at 31/10/2012), and the rate
of seclusion room use was also documented.
Data analyses
All analyses were carried out using statistical application
SPSS (version 19.0, IBM, Japan). The rate of concurrent
anti-Parkinson, benzodiazepine and mood stabilizer use
and seclusion room use were analyzed using Fisher’s
exact tests. The medicine costs and the dose and num-
ber of antipsychotics were evaluated using Wilcoxon
signed-rank test. The medicine costs, calculated as cost
per day, were recorded in USD ($1 = 123 Japanese Yen ).
P < 0.05 was considered statistically significant.
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Results
Participant characteristics
A total of 63 patients participated in this study, with
53.9 % of them being men. Among the participants, ten
patients had severe symptoms and/or adverse events.
One patient was discharged from the hospital before
completing the study. Thus, 52 participants completed
the study. The average age and illness duration of the
participants were 51.6 (SD, 16.8) years and 264.9 (SD,
183.4) months, respectively.
Effect on physician prescribing, rate of seclusion room
use, and medicine costs
As shown in Table 1, the dose and the number of
antipsychotic agents were significantly reduced in the
post-intervention group as compared with the pre-
intervention group (P < 0.001 and P < 0.05, respectively).
The prevalence of as a proportion of antipsychotic
polypharmacy in pre- and post-intervention was 73.1
and 63.5 %, respectively. Although there were no sig-
nificant differences in the rate of concurrent medica-
tion use, there was a trend towards lower seclusion
room use in the post-intervention group (P = 0.077).
The cost (in USD) per day of all medicine was signifi-
cantly reduced from a median of $10.33 pre-
intervention to $8.76 post-intervention (P < 0.05).
Additionally, the costs of antipsychotics from $8.04 to
$6.48 (P < 0.05), and psychotropic agents, from $9.42
to $7.68 (P < 0.005), were also significantly reduced.
Discussion
Despite the paucity of data, antipsychotic polypharmacy
remains a common practice [16], with an estimated use
among individuals with schizophrenia ranging from 10
to 30 % [1].
In this study, we evaluated the effect of pharmacist
intervention on physician prescribing. In comparison
with the pre-intervention group, the dose and number
of antipsychotics in the post-intervention group were
significantly lower. With regards to psychotic symp-
toms, as measured by the rate of seclusion room use,
there was a downward trend. Algorithms and guide-
lines recommend antipsychotic monotherapy as the
preferred option [17, 18], and it is generally accepted
that the optimal dose of antipsychotics for schizo-
phrenia is 300–800 mg per day chlorpromazine
equivalent [19]. In this study, the doses of antipsy-
chotics pre-intervention were beyond these criteria in
many patients. Previous studies have shown that re-
ducing the dose and the number of antipsychotic
agents increased the Global Assessment of Function-
ing value significantly [20, 21]. Extrapolating this find-
ing to our results, we speculate that reducing the
dose of antipsychotic agents may have been related to
the improvement in symptoms. It has been suggested
that the high doses of antipsychotics together with
polypharmacy, often undertaken by psychiatrists,
could adversely complicate medication therapy.
In this study, seclusion room use was used as an index
of symptomatic psychosis, but many studies use the
Positive and Negative Syndrome Scale (PANSS) and
Brief Psychiatric Rating Scale (BPRS) to measure psychi-
atric symptoms of schizophrenia [22]. However, these
scores are based on physician subjectivity, unlike the se-
clusion room use, which is based on both physicians’
and other healthcare professionals’ opinions. Previous
reports also cite seclusion room use as an index of
symptomatic schizophrenia [23], yielding similar results
to our study, in which the intervention group is more ef-
fective than the non-intervention group. A possible ex-
planation for this trend is that all antipsychotics possess
Table 1 Effects of pharmacist intervention on physician prescribing, frequency of seclusion use, and medicine costs
Pre-intervention in 2011 (n = 52) Post-intervention in 2012 (n = 52) p-value
Antipsychotic
dose (mg) 982.6 (200.0–2395.1) 857.6 (75.0–2418.6) p < 0.001
No. of medicine(s) 2.0 (1.0–6.0) 2.0 (1.0–5.0) p = 0.025
Concurrent agent n (%)
anti-Parkinson 25 (48.1) 24 (46.2) p = 0.500
benzodiazepine 42 (80.8) 38 (73.1) p = 0.243
mood stabilizer 28 (53.8) 30 (57.5) p = 0.423
Seclusion room use n (%) 23 (44.2) 15 (28.8) p = 0.077
Cost (USD)
all medicine 10.33 (1.33–104.79) 8.76 (0.45–34.16) p = 0.045
antipsychotic 8.04 (0.25–32.47) 6.48 (0.25–33.66) p = 0.016
psychotropic 9.42 (0.25–64.12) 7.68 (0.25–34.05) p = 0.004
Continuous variables indicate the median, and range in parentheses
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a dopamine-2 receptor antagonistic effect, which is
the mechanism for suppression of symptoms of
schizophrenia. However, excessive antagonism with
large antipsychotic doses and polypharmacy results in
up-regulation and super sensitivity at the receptor
level [24]. Therefore, psychosis might be exacerbated
despite compliance with the medication. To manage
the acute phase of psychosis, many psychiatrists often
have a tendency to add multiple antipsychotics result-
ing in polypharmacy [25]. This provides only transient
relief of symptoms, and physicians remain unsure of
which medicines are effective and are consequently
reluctant to remove any antipsychotics [26]. The re-
sultant effect is excessive sedation. Therefore, to avoid
undesirable adverse effects such as sedation when
treating acute symptoms of psychosis, physicians need
to prescribe optimal dose of antipsychotics. If symp-
toms remain and are treatment-resistant, rather than
introduce additional agents, or increase the dose of
existing antipsychotics, physicians should prescribe
agents with a different mechanism of action (such as
benzodiazepine or mood stabilizer) for a brief period.
A previous study showed that augmentation of anti-
psychotics with valproic acid, a mood stabilizer, was
useful in patients with schizophrenia [27]. With this
approach, the excessive antagonistic action against
dopamine-2 receptors is avoided. Our study found
that, despite a reduction in the number of antipsy-
chotics prescribed, there was no difference in concur-
rent benzodiazepine and mood stabilizer use between
the pre-intervention and post-intervention groups.
The reason for this might be in our strategy for
tapering the antipsychotics. For pharmaceutical inter-
vention, benzodiazepines and mood stabilizers were
first discontinued. After confirming any changes in
psychological symptoms, antipsychotics were then
gradually tapered off. However, if symptoms became
exacerbated, physicians were not allowed to prescribe
antipsychotics but were requested to reinstate a
benzodiazepine and/or mood stabilizer. Thus, concur-
rent use of benzodiazepine and mood stabilizers was
not reduced in this study.
Regarding medicine costs, few data are available,
particularly studies reporting cost–benefit of pharma-
cist intervention in Japanese hospitals. The cost per
patient per day of all medicines, antipsychotic medicines,
and psychotropic agents were significantly lower post-
intervention compared with pre-intervention. A cost re-
duction of $1.60 per day extrapolates to a cost reduction
of $584.00 per year. As described above, to optimize the
antipsychotics, we recommended that physicians use ad-
junctive benzodiazepine and/or mood stabilizer. However,
in this study, the cost of psychotropic agents was also
lower, despite no changes in the co-administration ratio.
This suggests that another medicine was removed, such as
laxatives for constipation.
Given the current estimation of 125,000 patients re-
ceiving antipsychotic polypharmacy [28], it would be
easy to extrapolate that pharmacist intervention would
lead to large economic savings.
There were several limitations to this study. First,
because this study was a pre/post design, no concur-
rent control group was included as each patient
served as his or her own control. Therefore, there
was no selection bias. As for confounders, the partici-
pants were all inpatients and thus received no other
therapy. However, natural healing over time could be
considered a confounding factor. Second, as the
targeted hospital was only one site, the number of
participants was low. Third, although it is common
for physicians to assess symptoms of schizophrenia
using PANSS and BPRS, we evaluated the symptoms/
severity using only the measure of seclusion. To fully
elucidate the schizophrenia symptoms/severity, the
subjective and objective opinions of physicians and
other healthcare professionals would be needed. Finally,
considering that we excluded ten patients from pharma-
ceutical intervention owing to any cause, pharmaceutical
intervention might be limited to patients who were suffi-
ciently stable. Therefore, to accurately determine the con-
tribution of clinical pharmacists to physician prescribing,
a multi-center large-scale randomized study would be
needed.
Conclusion
In this study, we evaluated the usefulness of clinical
pharmacist intervention on physician prescribing.
The dose and the number of antipsychotics were sig-
nificantly reduced without an increase in concurrent
benzodiazepine and mood stabilizer use following
pharmacist intervention. Additionally, seclusion room
use tended to be lower and a significant reduction
was observed in medicine costs. This suggests that
including a clinical pharmacist as one of the multi-
disciplinary team contributes not only to optimizing
physician prescribing but also to the healthcare
economy.
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